TY - JOUR
T1 - Ketogenic diet suppresses colorectal cancer through the gut microbiome long chain fatty acid stearate
AU - Tsenkova, Mina
AU - Brauer, Madita
AU - Pozdeev, Vitaly Igorevich
AU - Kasakin, Marat
AU - Busi, Susheel Bhanu
AU - Schmoetten, Maryse
AU - Cheung, Dean
AU - Meyers, Marianne
AU - Rodriguez, Fabien
AU - Gaigneaux, Anthoula
AU - Koncina, Eric
AU - Gilson, Cedric
AU - Schlicker, Lisa
AU - Herebian, Diran
AU - Schmitz, Martine
AU - de Nies, Laura
AU - Mayatepek, Ertan
AU - Haan, Serge
AU - de Beaufort, Carine
AU - Cramer, Thorsten
AU - Meiser, Johannes
AU - Linster, Carole L.
AU - Wilmes, Paul
AU - Letellier, Elisabeth
N1 - Funding:
This work was supported by the Luxembourg National
Research Fund (FNR) (grant nos. CORE/C16/BM/11282028 (E.L.), PoC/18/
12554295 (E.L.), AFR 17103240 (C.G.), PRIDE17/11823097 (M.T., M.K.,
L.d.N.) and CORE/15/BM/10404093 (P.W.)), by the Luxembourg National
Research Fund and the Fondation Cancer Luxembourg (grant no. CORE/
C20/BM/14591557 (E.L.)), as well as by the Fondation du Pélican de Mie
and Pierre Hippert-Faber under the aegis of the Fondation de Lux-
embourg (‘Pelican Grant’; M.T. and M.M.), a FNRS-Télévie grant to M.M.,
no. 7.4565.21-40007364), an Internal Research Project at the University
of Luxembourg (MiDiCa—integrated analysis of the effects of
microbiome-diet interactions on human colorectal adenocarcinoma
enterocytes; E.L., P.W. and S.H.), the Fondation Cancer and the Fonda-
tion Kriibskrank Kanner Luxembourg (V.I.P), the Action LIONS Vaincre le
Cancer Luxembourg and a European Research Council grant under the
European Union’s Horizon 2020 research and innovation program (grant
agreement no. 863664 to P.W.). This project was also supported by the
Doctoral School in Science and Engineering (M.T., M.K., M.M. and L.d.N.)
and the Department of Life Sciences and Medicine at the University of
Luxembourg.
Publisher Copyright:
© The Author(s) 2025.
PY - 2025/2/20
Y1 - 2025/2/20
N2 - Colorectal cancer (CRC) patients have been shown to possess an altered gut microbiome. Diet is a well-established modulator of the microbiome, and thus, dietary interventions might have a beneficial effect on CRC. An attenuating effect of the ketogenic diet (KD) on CRC cell growth has been previously observed, however the role of the gut microbiome in driving this effect remains unknown. Here, we describe a reduced colonic tumor burden upon KD consumption in a CRC mouse model with a humanized microbiome. Importantly, we demonstrate a causal relationship through microbiome transplantation into germ-free mice, whereby alterations in the gut microbiota were maintained in the absence of continued selective pressure from the KD. Specifically, we identify a shift toward bacterial species that produce stearic acid in ketogenic conditions, whereas consumers were depleted, resulting in elevated levels of free stearate in the gut lumen. This microbial product demonstrates tumor-suppressing properties by inducing apoptosis in cancer cells and decreasing colonic Th17 immune cell populations. Taken together, the beneficial effects of the KD are mediated through alterations in the gut microbiome, including, among others, increased stearic acid production, which in turn significantly reduces intestinal tumor growth.
AB - Colorectal cancer (CRC) patients have been shown to possess an altered gut microbiome. Diet is a well-established modulator of the microbiome, and thus, dietary interventions might have a beneficial effect on CRC. An attenuating effect of the ketogenic diet (KD) on CRC cell growth has been previously observed, however the role of the gut microbiome in driving this effect remains unknown. Here, we describe a reduced colonic tumor burden upon KD consumption in a CRC mouse model with a humanized microbiome. Importantly, we demonstrate a causal relationship through microbiome transplantation into germ-free mice, whereby alterations in the gut microbiota were maintained in the absence of continued selective pressure from the KD. Specifically, we identify a shift toward bacterial species that produce stearic acid in ketogenic conditions, whereas consumers were depleted, resulting in elevated levels of free stearate in the gut lumen. This microbial product demonstrates tumor-suppressing properties by inducing apoptosis in cancer cells and decreasing colonic Th17 immune cell populations. Taken together, the beneficial effects of the KD are mediated through alterations in the gut microbiome, including, among others, increased stearic acid production, which in turn significantly reduces intestinal tumor growth.
UR - http://www.scopus.com/inward/record.url?scp=85218501725&partnerID=8YFLogxK
U2 - 10.1038/s41467-025-56678-0
DO - 10.1038/s41467-025-56678-0
M3 - Article
C2 - 39979287
AN - SCOPUS:85218501725
SN - 2041-1723
VL - 16
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1792
ER -